Compounds > mdl 27048
Page last updated: 2024-12-11

mdl 27048

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MDL 27048: structure given in first source; powerful & reversible microtubule inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6439188
CHEMBL ID9652
SCHEMBL ID2389546
SCHEMBL ID2389541
MeSH IDM0171801

Synonyms (14)

Synonym
124711-23-5
1-(2,5-dimethoxyphenyl)-3-(4-(dimethylamino)phenyl)-1-methyl-2-propen-1-one
mdl-27048
2-propen-1-one, 1-(2,5-dimethoxyphenyl)-3-(4-(dimethylamino)phenyl)-2-methyl-, (e)-
mdl 27048
CHEMBL9652 ,
bdbm50070103
(e)-1-(2,5-dimethoxy-phenyl)-3-(4-dimethylamino-phenyl)-2-methyl-propenone
1-(2,5-dimethoxy-phenyl)-3-(4-dimethylamino-phenyl)-2-methyl-propenone
(e)-1-(2'',5''-dimethoxyphenyl)-3-(4''''-n,n-dimethylaminophenyl)-2-methylprop-2-en-1-one
SCHEMBL2389546
SCHEMBL2389541
trans-1-(2,5-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-methyl-2-propen-1-one
(e)-1-(2,5-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-methylprop-2-en-1-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin alpha-1A chainSus scrofa (pig)IC50 (µMol)0.01200.00672.160310.0000AID214695
Tubulin beta-1 chainHomo sapiens (human)IC50 (µMol)10.00000.00051.987010.0000AID241105
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID452433Cell cycle arrest in human K562 cells assessed as accumulation at G2/M phase at 20 nM after 24 hrs by propidium iodide staining-based flow cytometry2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID86837In vitro antimitotic activity against HeLa cells after 1 hr exposure to the compound1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID1435105Inhibition of cytoplasmic microtubule network assembly in rat-kangaroo PtK2 cells assessed as time required to reorganize cytoplasmic microtubule network measured post compound washout2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Synthesis and biological evaluation of 4 arylcoumarin analogues as tubulin-targeting antitumor agents.
AID40600The ratio of survival time for treated divided by survival time of control x 100 at a dose of 25 mg/kg in B16 melanoma cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID99291The ratio of survival time for treated divided by survival time of control x 100 at a dose of 12.5 mg/kg in L1210 leukemia cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID40599The ratio of survival time for treated divided by survival time of control x 100 at a dose of 12.5 mg/kg in B16 melanoma cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID1459264Induction of reactive oxygen species generation in human MCF7 cells assessed as decrease in cell viability at 10 uM in presence of N-acetyl cysteine after 48 hrs by alamarBlue assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents.
AID214695Tested for inhibition of polymerization of tubulin1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Potent antimitotic and cell growth inhibitory properties of substituted chalcones.
AID452431Cell cycle arrest in human K562 cells assessed as accumulation at G0/G1 phase at 20 nM after 24 hrs by propidium iodide staining-based flow cytometry2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID1435104Inhibition of cytoplasmic microtubule network assembly in rat-kangaroo PtK2 cells assessed as microtubule reassembly time measured post compound washout2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Synthesis and biological evaluation of 4 arylcoumarin analogues as tubulin-targeting antitumor agents.
AID94656Compound was evaluated for cytotoxic activity against K562 human chronic myelogenous leukemia cell line using MTT assay1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Potent antimitotic and cell growth inhibitory properties of substituted chalcones.
AID452436Binding affinity to tubulin in african green monkey Vero cells assessed as aberration of microtubule arrangement at 10 uM after 40 mins by immunohistochemistry2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID99293The ratio of survival time for treated divided by survival time of control x 100 at a dose of 50 mg/kg in L1210 leukemia cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID452430Antiproliferative activity against human K562 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID86838In vitro antimitotic activity against HeLa cells after 6 hours exposure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID452432Cell cycle arrest in human K562 cells assessed as accumulation at S phase at 20 nM after 24 hrs by propidium iodide staining-based flow cytometry2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID99294The ratio of survival time for treated divided by survival time of control x 100 at a dose of 6.25 mg/kg in L1210 leukemia cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID452435Displacement of [3H]colchicine from tubulin assessed as bound colchicine at 0.05 to 10 mM incubated in dark for 2 hrs by scintillation spectroscopy2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID452434Inhibition of tubulin assembly by Woods method2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID99292The ratio of survival time for treated divided by survival time of control x 100 at a dose of 25 mg/kg in L1210 leukemia cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
AID241105Concentration required for 50% inhibition of tubulin polymerization2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's4 (40.00)18.2507
2000's3 (30.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nocodazole
[no description available]		2.1510aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		7.9240alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.0310furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
vinblastine
[no description available]		1.9710
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.1510taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
methotrexate
[no description available]		2.0510dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
4-phenylcoumarin
4-phenylcoumarin: structure given in first source. 4-phenylcoumarin : The simplest member of the class of neoflavones that is coumarin substituted by a phenyl group at position 4.		2.1510neoflavones
chalcone
trans-chalcone : The trans-isomer of chalcone.		3.2460chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
piplartine
piplartine: Antineoplastic Agent, Phytogenic; alkaloid from Piper; structure in first source		2.1510cinnamamides;
dicarboximide
4-hydroxycinnamoylmethane
4-hydroxycinnamoylmethane: RN given refers to cpd without isomeric designation. p-hydroxyphenylbut-3-ene-2-one : An enone in which a 4-hydroxyphenyl group is attached to the beta-carbon atom of but-3-en-2-one.		1.9910
fosbretabulin
[no description available]		2.9940stilbenoid
1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene
[no description available]		2.0210
metochalcone
metochalcone: structure		2.0510
3',4',5',3,4,5-hexamethoxy-chalcone
[no description available]		2.0510
4-dimethylamino-2',4',6'-trimethoxychalcone
[no description available]		1.9710aromatic compound
combretastatin a-4 disodium phosphate
[no description available]		2.0510
3-hydroxy-4,3',4',5'-tetramethoxychalcone
3-hydroxy-4,3',4',5'-tetramethoxychalcone: structure in first source		2.7130
3,4-methylenedioxy-3',4',5'-trimethoxy chalcone
[no description available]		2.4220
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.1510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1510